I can do this review, but I **can‚Äôt complete Tasks 1‚Äì5 yet** because the `data.js` content you provided is **truncated mid-file** (it cuts off at `trm-12` with `Provides high sensitivity and precision not confound...`). That means I‚Äôm missing:

- the remainder of **TRM tests** (including `trm-12` fields and `trm-13`, `trm-14` mentioned in the header),
- **all TDS tests** and **TDS IVD kits** (including `tds-kit-13` referenced in the header),
- the full **ECD IVD kits** section (if any beyond what appears),
- the **DATABASE_CHANGELOG** section,
- any closing braces/arrays needed to reliably parse the dataset.

### What I need from you to proceed
Please upload the **complete `data.js` file** (as a file attachment or paste the remaining portion in one or more messages). Once I have the full file, I will:

- parse every entry by `id`,
- validate regulatory and reimbursement claims against authoritative sources (FDA PMA/510(k)/De Novo databases, CMS CLFS/PLA, MolDX LCDs, etc.),
- check citation URLs for accessibility and whether they actually support the stated metrics,
- search 2024‚Äì2025 literature/news for updates and missing tests,
- produce your requested tables: **CRITICAL | UPDATES | NEW INFO | MISSING TESTS | VERIFIED**.

### While we wait: immediate CRITICAL issues visible *in the provided portion* (needs full file to ensure no duplicates elsewhere)
Even from the partial content, I can already flag a few high-confidence issues to fix.

#### üî¥ CRITICAL (from the visible portion only)

| Test | Field | Current | Suggested | Source |
|------|-------|---------|-----------|--------|
| **NeXT Personal Dx (Personalis)** (`mrd-2`) | `sensitivityCitations` | Investor relations PDF link | Replace/add peer‚Äëreviewed analytical/clinical validation citations; investor deck is not an appropriate primary citation for performance claims (and can change/break). At minimum add the Personalis assay performance page + peer-reviewed paper(s) supporting sensitivity/specificity. | Personalis performance page: https://www.personalis.com/next-personal-assay-performance/ |
| **CancerDetect (IMBdx)** (`mrd-22`) | `lod95Citations` / `lodCitations` | `https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0302129` | This URL appears to point to a **different PLOS ONE article id than the one listed elsewhere for CancerDetect (e.g., `0334282`)**. Verify the correct PLOS ONE paper for analytical validation and update all PLOS IDs consistently. | PLOS ONE article lookup (verify exact DOI/ID): https://journals.plos.org/plosone/ |
| **Cancerguard appears twice** (`ecd-5` and `ecd-22`) | Duplicate test entries | Two separate ECD entries both named ‚ÄúCancerguard‚Äù | Deduplicate: keep **one canonical `id`**. Merge fields/citations and ensure consistent values across the database. | Exact Sciences launch PR (for canonical): https://www.exactsciences.com/newsroom/press-releases/exact-sciences-launches-cancerguard-first-of-its-kind-multi-cancer-early-detection-blood-test |
| **Shield (Guardant)** (`ecd-1`) | `reimbursementNote` | ‚ÄúMedicare coverage per NCD 210.3‚Äù | NCD 210.3 is the **colorectal cancer screening** NCD framework, but whether it specifically enumerates Shield and the precise frequency/eligibility should be confirmed in CMS NCD/manual and/or Guardant/CMS communications. I will verify and either cite exact CMS language or replace with ‚ÄúMedicare covered‚Äù + correct policy ref. | CMS NCD 210.3: https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=281 |

These are ‚Äúcritical‚Äù because they affect database integrity (duplicate test) or point to likely incorrect/mismatched citation identifiers.

---

## Next step
Upload the **complete `data.js`** and I‚Äôll return the full comprehensive, web-cited audit in the exact table format you requested (CRITICAL / UPDATES / NEW INFO / MISSING TESTS / VERIFIED).